Home > Archive > 2017 > 3

Volume 36, Number 3, pages 2-6

Should SGLT2 Inhibitors Be Used to Treat Type 1 Diabetes?

Kathleen Wyne, MD, PhD, Associate Professor, Division of Endocrinology, Diabetes and Metabolism The Ohio State University, Wexner Medical Center Columbus, Ohio

This question has garnered a great deal of interest since the first agents in the class received FDA approval for treating Type 2 diabetes. Clinical trial data involving people with Type 1 diabetes have shown some promising results. However, clinically significant safety concerns have limited the interest in further investigation of these agents for Type 1 diabetes.

Drug treatmentSodium-glucose cotransporter 2 inhibitors